NCT05315167View on ClinicalTrials.gov

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

May 15, 2027

Study Completion Date

November 15, 2027

Conditions
Advanced Solid TumorAdvanced Solid Malignancies
Interventions
DRUG

PRJ1-3024

PRJ1-3024 is provided as capsules and is administered orally once a day.

Trial Locations (5)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Unknown

RECRUITING

The first affiliated hospital of Zhengzhou University, Zhengzhou

RECRUITING

West China Hospital of Sichuan University, Chengdu

RECRUITING

Cancer hospital of the University of Chinese Academy of Sciences, Hangzhou

RECRUITING

The Fifth Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
lead

Zhuhai Yufan Biotechnologies Co., Ltd

INDUSTRY